Search clinical trials for: Degarelix

Total 147 results

Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
Ferring Pharmaceuticals

Completed

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

Prostate Cancer

Taiwan
Ferring Pharmaceuticals

Completed

Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Prostate Cancer

Netherlands, Belgium, Germany, Russian Federation, South Africa, Hungary, Romania, Poland
Astellas Pharma Inc

Completed

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Prostatic Neoplasms

Japan
Astellas Pharma Inc

Completed

Phase II Study of ASP3550 in Patients With Prostate Cancer

Prostatic Neoplasms

Japan
Ferring Pharmaceuticals

Completed

An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

Prostate Cancer

Belgium, Germany, Hungary, Netherlands, Romania, Russian Federation, South Africa
Ferring Pharmaceuticals

Completed

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) (DELUTS)

Lower Urinary Tract Symptoms (LUTS)

United States, Canada, Belgium, Czech Republic, Italy, Poland
Ferring Pharmaceuticals

Completed

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Ferring Pharmaceuticals

Completed

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
Ferring Pharmaceuticals

Completed

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

Prostate Cancer

Denmark, Sweden, Finland, Hungary, Norway, Romania, Russian Federation
VA Office of Research and Development

Completed

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH)

COVID-19

United States
Ferring Pharmaceuticals

Completed

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)

Prostate Cancer

France
Ferring Pharmaceuticals

Completed

A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Prostate Cancer

Finland, France, Germany
Ferring Pharmaceuticals

Completed

Safety and Efficacy of Firmagon® (Degarelix) for Injection

Prostate Cancer

Korea, Republic of
Ferring Pharmaceuticals

Completed

Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Advanced Hormone Sensitive Prostate Cancer

Netherlands
Ferring Pharmaceuticals

Completed

The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer

Prostate Cancer

United Kingdom
Rabin Medical Center
Ferring Pharmaceuticals

Unknown

Cardiovascular Events in GnRH Agonist vs. Antagonist

Prostate Cancer | Cardiac Event | Hormone Sensitive Prostate Cancer

Israel
Bioroma

Unknown

Long Acting GnRH Antagonist in PCOS Women Undergoing IVF

Ovarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome | Invitro Fertilization

Italy
UNICANCER
Ferring Pharmaceuticals

Active, not recruiting

Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy (GETUG-AFU22)

Adenocarcinoma of Prostate

France
Azienda Socio Sanitaria Territoriale degli Spedali...
Ferring Pharmaceuticals

Unknown

Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix (BLADE)

Prostate Cancer

Italy
Ferring Pharmaceuticals

Completed

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer (IM1)

Prostate Cancer

United States, Canada
Canadian Urology Research Consortium
Ferring Pharmaceuticals

Terminated

Firmagon (Degarelix) Intermittent Therapy (FIT)

Prostate Cancer Recurrent

Canada
Ferring Pharmaceuticals

Completed

Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.

BPH

Germany
Ferring Pharmaceuticals

Completed

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Czech Republic, Hungary, Romania, Canada
Aarhus University Hospital

Recruiting

Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer

Quality of Life | Bladder Cancer | Radiation Therapy Complication

Denmark
British Columbia Cancer Agency

Completed

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Prostate Cancer

Canada
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Prostate Cancer

Korea, Republic of
British Columbia Cancer Agency
Ferring Pharmaceuticals

Unknown

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Prostate Neoplasm

Canada
Ferring Pharmaceuticals

Terminated

Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients

Prostate Cancer
Ferring Pharmaceuticals

Completed

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

Prostate Cancer

China
Ferring Pharmaceuticals

Completed

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Prostate Cancer

Germany
Ferring Pharmaceuticals

Terminated

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Prostate Cancer
Ottawa Hospital Research Institute

Terminated

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (OTT10-06)

Prostatic Neoplasms

Canada
Ferring Pharmaceuticals

Completed

Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486

Prostate Cancer

United States
Ferring Pharmaceuticals

Terminated

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Prostate Cancer

United States
Ferring Pharmaceuticals

Completed

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

Prostate Cancer

United States, Belgium, Netherlands, Canada, Russian Federation, Finland, Former Serbia and Montenegro, France, Germany, Romania, United Kingdom
Turku University Hospital

Recruiting

The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer (ADTPSMA2)

Prostate Cancer

Finland
Ferring Pharmaceuticals

Completed

FIRMAGON Intensive Drug Monitoring Protocol

Prostate Cancer

China
Ferring Pharmaceuticals

Completed

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina (FAST AR)

Advanced Hormone Dependent Prostate Cancer

Argentina
Ferring Pharmaceuticals

Completed

An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer (PandaExtension)

Prostate Cancer

China
United Clinic Management GmbH

Completed

Treatment of Prostate Cancer With Firmagon®

Prostate Cancer

Germany
Ferring Pharmaceuticals

Completed

A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Prostate Cancer

India
Ferring Pharmaceuticals

Completed

A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

Prostate Cancer

Spain, France, Belgium, Italy, Sweden, Portugal, Turkey
University Health Network, Toronto
Bayer; Prostate Cancer Canada

Not yet recruiting

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC)

Prostate Cancer

Canada
University of Colorado, Denver

Active, not recruiting

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Menopause | Aging | Estrogen Deficiency | Women

United States
Assisting Nature

Unknown

Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix

Pregnancy, Ovarian

Greece
Ferring Pharmaceuticals

Completed

Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer

Prostate Cancer

Finland, Belgium, Netherlands, Russian Federation, Germany, Romania, United Kingdom, France, Montenegro, Serbia
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer

Prostate Cancer

United States
Ferring Pharmaceuticals

Completed

Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation (FACT)

Prostate Cancer

France
Ferring Pharmaceuticals

Completed

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

Prostate Cancer

United States, Canada

3

Subscribe